Shares of TrovaGene Inc (NASDAQ:TROV) were down 10.9% during mid-day trading on Wednesday . The stock traded as low as $0.39 and last traded at $0.41. Approximately 4,812,427 shares traded hands during trading, an increase of 122% from the average daily volume of 2,166,021 shares. The stock had previously closed at $0.46.
Several analysts have recently issued reports on TROV shares. Maxim Group reaffirmed a “hold” rating on shares of TrovaGene in a report on Wednesday, January 24th. ValuEngine raised TrovaGene from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. HC Wainwright started coverage on TrovaGene in a report on Thursday, December 21st. They set a “buy” rating and a $1.00 price objective on the stock. Finally, cut TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $4.33.
The stock has a market cap of $22.66, a price-to-earnings ratio of -0.54 and a beta of 0.06.
An institutional investor recently raised its position in TrovaGene stock. Susquehanna International Group LLP boosted its stake in shares of TrovaGene Inc (NASDAQ:TROV) by 254.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 488,937 shares of the medical research company’s stock after buying an additional 350,906 shares during the period. Susquehanna International Group LLP owned approximately 1.28% of TrovaGene worth $357,000 at the end of the most recent quarter. 4.63% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This story was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3262337/trovagene-trov-shares-down-10-9.html.
TrovaGene Company Profile
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.